Drug Profile


Alternative Names: Baraclude; BMS-200475; SQ 34676

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antivirals; Cyclopentanes; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; RNA-directed DNA polymerase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B
  • Discontinued Herpesvirus infections

Most Recent Events

  • 22 Mar 2017 Bristol-Myers Squibb plans a phase I trial for Hepatitis B in Japan (NCT03083821)
  • 15 Mar 2016 Biomarkers information updated
  • 05 Dec 2014 Entecavir is still in phase III trials for Hepatitis B (in adolescents, In children) in Argentina, Belgium, Canada, India, Israel, Russia and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top